Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909856 | 0.85 | CTSS (0.42) | CTSSCTSLCTSBCTSKTLR2 | |
| SCHEMBL16219332 | 0.83 | CTSL (0.52) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL14650073 | 0.83 | CTSS (0.48) | CTSSCTSLCTSBCTSKTLR2 | |
| SCHEMBL23387355 | 0.81 | CTSB (0.44) | CTSSCTSLCTSBCTSKTLR2 | |
| SCHEMBL28693731 | 0.80 | CTSS (0.50) | CTSSCTSLCTSBCTSKTLR2 | |
| SCHEMBL15575112 | 0.78 | NPC1 (0.50) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL29761503 | 0.78 | CTSL (0.47) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL22495659 | 0.78 | CTSS (0.48) | CTSSCTSLCTSBCTSKTLR2 | |
| SCHEMBL20744116 | 0.78 | JAK2 (0.47) | CTSSCTSLCTSBCTSKJAK2 | |
| SCHEMBL30184830 | 0.78 | CTSS (0.43) | CTSSCTSLCTSBCTSKTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| CN-111278840-A | Pyrrolo [2, 3-B ] pyridine compounds and their use for treating cancer | 癌症研究科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | CTSS 2877/4885CTSL 2560/4885CTSB 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.